KU-55933, competitive ATM kinase inhibitor (ab120637)
Key features and details
- Potent, selective, competitive ATM kinase inhibitor
- CAS Number: 587871-26-9
- Purity: > 99%
- Soluble in DMSO to 100 mM and in ethanol to 50 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
KU-55933, competitive ATM kinase inhibitor -
Description
Potent, selective, competitive ATM kinase inhibitor -
Biological description
Potent, selective and competitive ATM kinase inhibitor. IC50 values are 12.9 (ATM), 2000 (DNA-PK), 9300 (mTOR), 16600 (PI3K), >100000 (ATR) and >100000 nM (PI4K). Sensitizes cells to ionizing radiation and chemotherapeutics. Blocks Akt phosphorylation, induces G1 cell cycle arrest and induces apoptosis in breast and prostate cell lines.
-
Purity
> 99% -
CAS Number
587871-26-9 -
Chemical structure
Properties
-
Chemical name
2-(4-Morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-one -
Molecular weight
395.49 -
Molecular formula
C21H17NO3S2 -
PubChem identifier
5278396 -
Storage instructions
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 100 mM and in ethanol to 50 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
C1COCCN1C2=CC(=O)C=C(O2)C3=C4C(=CC=C3)SC5=CC=CC=C5S4 -
Source
Synthetic
-
Research areas
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab120637 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
|
Notes |
---|
Functional Studies
Use at an assay dependent concentration. |
Images
-
2D chemical structure image of ab120637, KU-55933, competitive ATM kinase inhibitor
-
HepG2 cells were incubated at 37°C for 60 minutes with vehicle control (0 µM) and different concentrations of KU-55933 (ab120637). Decreased expression of Acetyl Coenzyme A Carboxylase (phospho S79) (ab31931) in HepG2 cells correlates with an increase in KU-55933 concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab31931 at 1 µg /ml and ab8227 at 1 µg /ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (24)
ab120637 has been referenced in 24 publications.
- Zhang C et al. A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors. Signal Transduct Target Ther 8:183 (2023). PubMed: 37160887
- Isobe SY et al. Protein phosphatase 1 acts as a RIF1 effector to suppress DSB resection prior to Shieldin action. Cell Rep 36:109383 (2021). PubMed: 34260925
- Bunch H et al. BRCA1-BARD1 regulates transcription through modulating topoisomerase IIß. Open Biol 11:210221 (2021). PubMed: 34610268
- Uehara M et al. Pharmacological inhibition of ataxia-telangiectasia mutated exacerbates acute kidney injury by activating p53 signaling in mice. Sci Rep 10:4441 (2020). PubMed: 32157166
- Sun C et al. Re-equilibration of imbalanced NAD metabolism ameliorates the impact of telomere dysfunction. EMBO J 39:e103420 (2020). PubMed: 32935380